• Earlier in May 2026, Zai Lab announced the departure of President and COO Josh Smiley as part of a leadership reshuffle to improve operational efficiency, while continuing preparations for key product launches and clinical milestones.
• A few days earlier, the company had reported FDA Fast Track Designation for its investigational DLL3-targeting ADC zoci in extrapulmonary neuroendocrine carcinomas, highlighting progress in a cancer area with no established targeted options.
• We’ll now examine how the leadership change, alongside zoci’s new Fast Track status, affects Zai Lab’s existing long-term investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Zai Lab Investment Narrative Recap

To own Zai Lab, you need to believe its mix of China-focused commercialization and higher risk global oncology bets can eventually support a sustainable business, despite ongoing losses and reliance on partnered assets. The near term story still centers on execution for upcoming launches like COBENFY in China and clinical readouts from lead oncology programs. The leadership change and zoci Fast Track news do not materially alter those immediate catalysts or the overarching risk around profitability.

The most directly relevant update is the new FDA Fast Track Designation for zoci in extrapulmonary neuroendocrine carcinomas, backed by early data from a registration-enabling Phase 1b/2 trial. This strengthens zoci’s role as a key clinical and potential commercial catalyst alongside its existing Fast Track status in small cell lung cancer and multiple planned registration-enabling studies. How effectively Zai Lab advances zoci while adjusting its leadership structure will be central to whether the long term thesis holds.

Yet beneath the excitement around zoci and pipeline progress, investors should also be aware of the risk that sustained high R&D and SG&A spend could...

Zai Lab's narrative projects $794.1 million revenue and $101.4 million earnings by 2029.

Uncover how Zai Lab's forecasts yield a $35.34 fair value, a 90% upside to its current price.

Exploring Other Perspectives

Before this leadership shake up, the most bullish analysts were assuming revenue could reach about US$1.7 billion and earnings US$353.7 million by 2028, which paints a far more optimistic picture than consensus. Set against ongoing worries about clinical and regulatory execution, this spread in expectations is a useful reminder that your own view on today’s news may lead you toward a very different narrative than the one baked into those earlier forecasts.

Explore 4 other fair value estimates on Zai Lab - why the stock might be worth just $21.80!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zai Lab research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zai Lab research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zai Lab's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.